Font Size: 

Background: Low dose aspirin is the most common drug used for prevention of cardiovascular and cerebrovascular event. Long-term aspirin therapy can induces gastroduodenal mucosal injury, even in a very low dose (10 mg daily). The frequency of gastroduodenal injuries among long-term low-dose aspirin users in Indonesia is currently unknown. This study aimed to determine the gastroduodenal mucosal injury prevalence, endoscopic findings, and influencing factors among long-term low-dose aspirin users. Methods: This study was a cross-sectional study conducted in Cipto Mangunkusumo Hospital, Jakarta. Subjects were ≥ 18 years old patients that have been using low-dose aspirin (75-325 mg) for at least 28 days. Ninety five subjects were recruited consecutively in the period of December 2015 – April 2016. Endoscopic findings such as erosions and ulcers were assessed as mucosal injuries. Data were extracted to find prevalence, bivariate analysis (Chi Square test), and multivariate analysis (logistic regression test). Results: Mucosal injury was found in 49 subjects [51.6% (95% CI 41.6–61.7%)]; mucosal erosion in 38 subjects [40% (95% CI 30.2–49.9%)] and ulcers in 11 subjects [11.6% (95% CI 5.2–18.0%)]. Only 44.9% patients with mucosal injury had dyspepsia symptoms. Double antiplatelet therapy increases the risk of mucosal injury [OR 3.3 (95% CI 1.3–8.5)]. However, proton pump inhibitor (PPI) decreases the risk of mucosal injury [OR 0,2 (95% IK 0,04 – 0,60)]. Conclusions: Gastroduodenal mucosal injury was found in more than half of long-term low-dose aspirin users. Double antiplatelet therapy increases the risk of mucosal injury, while PPI effectively reduced the risk.